The 4th of 6 published General Laboratory families by billed volume.
Medicare reported an estimated 50.4 million Immunoassay services in the United States in 2024
In 2024, Medicare's fee-for-service record carried about 24.8 million Immunoassay billed services in the United States; scaled for Medicare Advantage — roughly half of Medicare enrollment — that is an estimated 50.4 million services, or about 887 per 1,000 fee-for-service beneficiaries.
This counts reported Medicare Immunoassay SERVICES — billed services, not procedures, visits, transports, or people. A single episode can bill several services, and one person can be served many times, so this is a volume of billed services and nothing more. On the fee-for-service record the 2024 volume was about 24.8 million billed services; scaled to total Medicare enrollment it is an estimated 50.4 million. Assumption-free, that is about 887 Immunoassay services per 1,000 fee-for-service beneficiaries. Across 2015–2024 the estimated total moved about 1.5 times (about 1.1 times on the fee-for-service record alone, before the Medicare Advantage adjustment).
Reported Medicare fee-for-service Immunoassay billed services, 2015 to 2024, scaled to total Medicare enrollment, with the assumption-free per-1,000-beneficiary rate stated alongside.
Not a count of procedures, visits, transports, or people (a services-volume count — one episode can bill several services), not Medicare Advantage measured directly, not all-payer, and not a care-quality or need signal. The scaled figures are estimates: the calculation assumes MA per-capita utilization ≈ FFS; MA plans may manage utilization differently. The per-1,000 rate is on the fee-for-service record and is not scaled.